[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001296800A1 - Systemic delivery of compounds through non-invasive bladder administration - Google Patents

Systemic delivery of compounds through non-invasive bladder administration

Info

Publication number
AU2001296800A1
AU2001296800A1 AU2001296800A AU9680001A AU2001296800A1 AU 2001296800 A1 AU2001296800 A1 AU 2001296800A1 AU 2001296800 A AU2001296800 A AU 2001296800A AU 9680001 A AU9680001 A AU 9680001A AU 2001296800 A1 AU2001296800 A1 AU 2001296800A1
Authority
AU
Australia
Prior art keywords
compounds
systemic delivery
invasive bladder
bladder administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296800A
Inventor
Michael F. Haller
Kam W Leong
Catherine S. Levisage
Bernard A. Malavaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001296800A1 publication Critical patent/AU2001296800A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001296800A 2000-10-06 2001-10-05 Systemic delivery of compounds through non-invasive bladder administration Abandoned AU2001296800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23850500P 2000-10-06 2000-10-06
US60/238,505 2000-10-06
PCT/US2001/031739 WO2002028372A2 (en) 2000-10-06 2001-10-05 Systemic delivery of compounds through non-invasive bladder administration

Publications (1)

Publication Number Publication Date
AU2001296800A1 true AU2001296800A1 (en) 2002-04-15

Family

ID=22898202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296800A Abandoned AU2001296800A1 (en) 2000-10-06 2001-10-05 Systemic delivery of compounds through non-invasive bladder administration

Country Status (3)

Country Link
US (1) US6797704B2 (en)
AU (1) AU2001296800A1 (en)
WO (1) WO2002028372A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG125885A1 (en) * 2000-12-05 2006-10-30 Univ Singapore A polymer and nerve guide conduits formed thereof
US20040260272A1 (en) * 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
AU2004241111B2 (en) 2003-05-15 2010-05-27 Dsm Ip Assets B.V Manufacture and use of implantable reticulated elastomeric matrices
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
EP1758633B1 (en) * 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Methods for compounding a therapeutic agent to the adventitia of a vessel
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US9089601B2 (en) * 2006-07-10 2015-07-28 University Of Rochester Pre- and intra-operative imaging of bladder cancer
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
EP2139513B1 (en) * 2007-03-28 2012-09-05 National Institute of Immunology Polymer particles based vaccine
ATE530178T1 (en) 2007-05-23 2011-11-15 Amcol International Corp PHYLLOSSILICATES INTERACTING WITH CHOLESTEROL AND METHOD FOR REDUCING HYPERCHOLESTEROLEMIA IN A MAMMAL
EP2175841A1 (en) * 2007-07-16 2010-04-21 Aarhus Universitet Osteopontin nanoparticles system for drug delivery
CN102066937A (en) 2008-01-25 2011-05-18 P53股份有限公司 P53 biomarker
US8293535B2 (en) * 2009-11-02 2012-10-23 Lawrence Livermore National Security, Llc Bio-threat microparticle simulants
US9023650B2 (en) 2009-11-02 2015-05-05 Lawrence Livermore National Security, Llc DNA tagged microparticles
WO2011069528A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
US8865123B1 (en) 2010-09-16 2014-10-21 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US9119887B2 (en) 2010-09-16 2015-09-01 Mo-Sci Corporation Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging
US9849200B2 (en) 2010-09-16 2017-12-26 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
WO2018169960A1 (en) * 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6548302B1 (en) * 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
WO2001068052A2 (en) * 2000-03-10 2001-09-20 Johns Hopkins University Phosphate based biodegradable polymers

Also Published As

Publication number Publication date
WO2002028372A3 (en) 2002-10-17
WO2002028372A2 (en) 2002-04-11
US6797704B2 (en) 2004-09-28
US20020172717A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
AU2001296800A1 (en) Systemic delivery of compounds through non-invasive bladder administration
AU2001279064A1 (en) Therapeutic azo-compounds for drug delivery
AU2002322719A1 (en) Delivery of therapeutic capable agents
PL370889A1 (en) Vaginal delivery of drugs
AU2002246925A1 (en) Therapeutic delivery balloon
AU2002232618A1 (en) Tissue attachable drug delivery catheters/methods of use
AU2001270300A1 (en) Drug delivery formulations and targeting
AU2001227858A1 (en) Delivery of cardiac constraint jacket
AU2001264887A1 (en) Drug delivery device
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2002218250A1 (en) Medicament dispenser
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL152593A0 (en) Liposome drug delivery
AU2002223562A1 (en) Medicament dispenser
AU2002211602A1 (en) Polymer controlled delivery of a therapeutic agent
AU2001243515A1 (en) Combination drug therapy
AU2002243290A1 (en) Transluminal drug delivery catheter
HUP0303597A3 (en) Diposable vaginal cannula for the simultaneous administration of drugs in different forms
AU2001284125A1 (en) Medicine for fighting against sexual dysfunction
AU2002218750A1 (en) Photoactivated drug therapy
AU6503399A (en) Drug delivery catheter
AUPR277401A0 (en) Physiologically active bracing
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof